| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/06/2001 | WO2001092289A1 SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1 |
| 12/06/2001 | WO2001092282A2 Methods and compositions for treating flaviviruses and pestiviruses |
| 12/06/2001 | WO2001092280A1 Hygromycin a derivatives for the treatment of bacterial and protozoal infections |
| 12/06/2001 | WO2001092274A2 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 12/06/2001 | WO2001092268A1 Process for drying amoxicillin |
| 12/06/2001 | WO2001092267A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | WO2001092264A1 Adenosine a2a receptor antagonists |
| 12/06/2001 | WO2001092262A1 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
| 12/06/2001 | WO2001092261A1 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092260A1 4-(2-phenylthiazol-5-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092259A1 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092241A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors |
| 12/06/2001 | WO2001092239A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | WO2001092238A1 Amorphous oxazole coumpound and its use as cox-2 inhibitor |
| 12/06/2001 | WO2001092235A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 12/06/2001 | WO2001092233A1 3-substituted isoquinolin-1-yl derivatives |
| 12/06/2001 | WO2001092232A1 4-aminoquinolines as antiinfective agents |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092229A1 TNF-α PRODUCTION INHIBITORS |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092226A1 Heterocyclic analgesic compounds and method of use thereof |
| 12/06/2001 | WO2001092224A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092213A2 Excitatory amino acid receptor modulators |
| 12/06/2001 | WO2001092212A1 Excitatory amino acid receptor modulators |
| 12/06/2001 | WO2001092210A1 Compounds for modulating the rage receptor |
| 12/06/2001 | WO2001092204A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 12/06/2001 | WO2001092202A1 Il-8 receptor antagonists |
| 12/06/2001 | WO2001091856A2 Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation |
| 12/06/2001 | WO2001091814A2 Polyubiquitin based hydrogel and uses thereof |
| 12/06/2001 | WO2001091796A2 Methods, compounds and compositions for treating gout |
| 12/06/2001 | WO2001091795A1 Ectocornea extension promoters |
| 12/06/2001 | WO2001091789A2 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | WO2001091786A2 Diagnosis and treatment of herpes infections |
| 12/06/2001 | WO2001091785A2 Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 12/06/2001 | WO2001091783A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 12/06/2001 | WO2001091775A2 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 12/06/2001 | WO2001091772A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091770A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091769A2 Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091768A2 Compositions for treating brain disorders and enhancing brain function, containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091767A2 Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091765A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091764A2 Extracts from spermatophyte plants with immunomodulating activity |
| 12/06/2001 | WO2001091763A2 Extracts from spermatophyte plants with antitumor activity |
| 12/06/2001 | WO2001091762A1 Zinc-supplementary compositions for oral administration |
| 12/06/2001 | WO2001091761A1 Matrices for oral preparations |
| 12/06/2001 | WO2001091760A1 New use |
| 12/06/2001 | WO2001091759A1 Treatment of side effects associated with alcohol consumption |
| 12/06/2001 | WO2001091758A1 Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof |
| 12/06/2001 | WO2001091757A1 Percutaneous absorption type steroid preparation for external use |
| 12/06/2001 | WO2001091756A2 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| 12/06/2001 | WO2001091754A1 Protein kinase inhibitors |
| 12/06/2001 | WO2001091752A1 Melanocortin receptor agonists |
| 12/06/2001 | WO2001091751A1 New pharmaceutical composition and the process for its preparation |
| 12/06/2001 | WO2001091750A1 Use of a celecoxib composition for fast pain relief |
| 12/06/2001 | WO2001091749A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
| 12/06/2001 | WO2001091748A2 Methods for prevention of ulcers and improving physiological performance |
| 12/06/2001 | WO2001091747A1 Use of ace inhibitors for treatment of patients suffering from behavioral disorders |
| 12/06/2001 | WO2001091746A1 Method for treating alcohol intoxication and alcohol abuse |
| 12/06/2001 | WO2001091745A2 Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions |
| 12/06/2001 | WO2001091744A1 Methods of treating androgen deficiency in men using selective antiestrogens |
| 12/06/2001 | WO2001091743A1 Patch containing 4-biphenylacetic acid |
| 12/06/2001 | WO2001091742A1 Pharmaceutical composition containing at least a polymer associated or conjugated with at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof |
| 12/06/2001 | WO2001091741A2 Compositions containing hexitol and an antiproliferative agent |
| 12/06/2001 | WO2001091740A2 Compositions containing naphthaquinone and an antiproliferative agent |
| 12/06/2001 | WO2001091739A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 12/06/2001 | WO2001091738A2 Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| 12/06/2001 | WO2001091737A2 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 12/06/2001 | WO2001091736A2 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| 12/06/2001 | WO2001091735A2 Use of aloe-emodin in the treatment of neuroectodermal tumors |
| 12/06/2001 | WO2001091734A2 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases |
| 12/06/2001 | WO2001091733A2 Combination of active substances containing montirelin and a compound having an opioid effect |
| 12/06/2001 | WO2001091732A2 Medicament for combating respiratory depression |
| 12/06/2001 | WO2001091731A1 Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine |
| 12/06/2001 | WO2001091729A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/06/2001 | WO2001091724A2 Transdermal delivery of lasofoxifene |
| 12/06/2001 | WO2001091720A2 Preparation of injectable suspensions having improved injectability |
| 12/06/2001 | WO2001091719A1 Nasal ointment based on white petroleum jelly |
| 12/06/2001 | WO2001091717A1 Oral delivery form comprising glipizide |
| 12/06/2001 | WO2001091716A1 Peroral therapeutic system comprising glipizide |
| 12/06/2001 | WO2001091715A2 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-d-glucopyranoside |
| 12/06/2001 | WO2001091696A2 Use of biguanide derivatives for making a medicine having a wound healing effect |
| 12/06/2001 | WO2001091658A1 Supplemental spine fixation device and method |
| 12/06/2001 | WO2001091657A1 Supplemental spine fixation device and method |
| 12/06/2001 | WO2001091633A1 A formula to manipulate blood glucose via the calculated ingestion of carbohydrate |
| 12/06/2001 | WO2001091590A1 Dietary supplement with antioxidant activity containing an alkanoyl carnitine and a combination of polyphenols extracted from cocoa |
| 12/06/2001 | WO2001091589A1 Dietary supplement with antioxidant activity comprising an alkanoyl carnitine and a combination of polyphenols extracted from trees or shrubs |
| 12/06/2001 | WO2001091588A1 Primary composition containing a lipophilic bioactive compound |
| 12/06/2001 | WO2001091587A2 Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain |
| 12/06/2001 | WO2001091557A1 Extracts of kava-kava |
| 12/06/2001 | WO2001091535A2 A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3h)furanone enthält |
| 12/06/2001 | WO2001070683A3 3-substituted-4-pyrimidone derivatives |
| 12/06/2001 | WO2001070236A8 Preventing and/or treating diabetes mellitus |
| 12/06/2001 | WO2001062760A3 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR |
| 12/06/2001 | WO2001060837A3 Polypeptoid pulmonary surfactants |